65,437 trials
Protective Device (Physical Object) · Aerosol Disease · Droplet Spread
Primary: Measuring the Time for Performing an Airway Procedure With or Without the Biocontainment Device. — 46; 37 time (seconds)
Ocular Redness
Primary: Ocular Redness — 0.46; 0.53; 0.40; 0.49 score on a scale
Metastatic Adenoid Cystic Carcinoma · Progressive Disease · Recurrent Adenoid Cystic Carcinoma
Primary: Assess the Objective Response Rate (ORR) to Axitinib and Avelumab Combination According to RECIST 1.1 Criteria. — 18 percentage of participants
Opioid-use Disorder · Opioid Use · Opioid Abuse
Primary: Opioid Prescription Rate — 0.0159; 0.0141; 0.0161; 0.0120 percent
Obesity · Anxiety Sensitivity · Eating
Primary: Anxiety Sensitivity Index-3 — 43.44; 43.00; 40.17; 40.69 score on a scale
Pain
Primary: Maximum Observed Plasma Concentration (Cmax) for Ibuprofen — 36879.50; 38875.03 nanogram per milliliter (ng/mL)
Asthma
Primary: Number of Participants With Adverse Events and Serious Adverse Events — 3; 2; 2; 3 Participants
Carpometacarpal Osteoarthritis
Primary: Australian Canadian OA Hand Index (AUSCAN) — 3.3; 1.3; 2.0; 1.6 score on a scale
Postoperative Pain · Breast Reconstruction
Primary: Post-op Pain Scores During Initial Hospitalization — 4.3; 3.3 score on a scale
Breast Cancer
Primary: Relative Change of ≥ 5% in Breast Density at 6 Months — 13; 8; 4 Participants — p=0.026
Healthy
Primary: Toll-like Receptor 4 Expression Pre- and Post-Treatment — 12.37; 6.36 % tlr expression (monocytes)
Common Cold
Primary: Reduction in Viral Load in the URT — 3.6; 3.3; 4.9; 4.1 log 10 copies/mL — p=0.7146
Heart Valve Diseases
Primary: Number of Deaths, Reinterventions, or Explants — 2; 0 Participants
Alzheimer's Disease
Primary: Number of Patients With Adverse Events (AEs) — 93 Participants
Violence in Adolescence · Social Interaction · Coping Skills
Primary: Participant Attendance — 0.62; 0.49; 0.71 proportion of sessions attended